Price · as of 2024-12-31
$783.50
Market cap 47.46B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $354.37 | -54.77% |
| Intrinsic Value(DCF) | $29,657.82 | +3,685.3% |
| Graham-Dodd Method(GD) | $161.45 | -79.39% |
| Graham Formula(GF) | $1,159.50 | +47.99% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $78.60 | $408.92 | $946,481.97 | $11.70 | $0.00 |
| 2018 | $122.73 | $74.51 | $24.49 | $7.60 | $83.70 |
| 2019 | $150.11 | $221.02 | $14,759.57 | $8.30 | $0.00 |
| 2020 | $310.66 | $221.40 | $28.68 | $0.00 | $583.50 |
| 2021 | $278.23 | $272.61 | $46,154.85 | $9.71 | $0.00 |
| 2022 | $341.30 | $144.35 | $26.60 | $0.00 | $111.08 |
| 2023 | $387.80 | $234.51 | $57,718.43 | $45.87 | $0.00 |
| 2024 | $594.21 | $354.37 | $45,757.88 | $161.45 | $1,159.50 |
AI valuation
Our deep-learning model estimates argenx SE's (ARGX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $354.37
- Current price
- $783.50
- AI upside
- -54.77%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$29,657.82
+3,685.3% upside
Graham-Dodd
$161.45
-79.39% upside
Graham Formula
$1,159.50
+47.99% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ARGX | argenx SE | $783.50 | 47.46B | -55% | +3,685% | -79% | +48% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $87.18 | 42.49B | -32% | -61% | -65% | -71% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| ALNY | Alnylam Pharmaceuticals, … | $332.92 | 44.15B | +155% | +6,378% | -95% | -49% | 135.73 | 53.96 | 11.47 | 73.50 | — | 53.96 | 81.77% | 13.51% | 8.45% | 73.28% | -134.35% | 6.82% | 1.62 | 1.99 | 2.76 | 2.51 | -0.68 | -20688.00% | 6519.00% | -119273.00% | 1.09% | 0.36 | -128.40% | 0.00% | 0.00% | 5.06% | 81.65 | 88.00 | 11.03 | 5.93 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| EW | Edwards Lifesciences Corp… | $86.47 | 50.77B | -6% | -55% | -72% | -59% | 47.67 | 4.93 | 8.40 | 33.68 | — | 6.85 | 78.13% | 26.97% | 17.69% | 10.52% | 19.08% | 7.99% | 0.01 | — | 3.72 | 2.12 | -1.98 | -7374.00% | 1155.00% | 36050.00% | 2.62% | 0.88 | 18.76% | 0.00% | 0.00% | 2.71% | 29.43 | 36.07 | 7.94 | 11.83 |
| HLN | Haleon plc | $11.07 | 49.3B | +256% | -54% | — | -81% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| IDXX | IDEXX Laboratories, Inc. | $656.73 | 52.44B | -34% | -40% | -88% | -64% | 48.13 | 31.77 | 11.85 | 35.33 | 213.11 | 47.15 | 61.80% | 31.60% | 24.62% | 66.20% | 45.37% | 31.89% | 0.67 | 35.54 | 1.17 | 0.76 | 0.61 | 2259.00% | 1042.00% | 3199.00% | 2.07% | 1.03 | 43.92% | 0.00% | 0.00% | 2.39% | 38.16 | 49.26 | 12.06 | 22.89 |
| REGN | Regeneron Pharmaceuticals… | $781.67 | 81.22B | -37% | -58% | -41% | -50% | 18.36 | 2.65 | 5.77 | 13.20 | 224.20 | 2.76 | 85.35% | 24.95% | 31.41% | 14.87% | 12.73% | 11.50% | 0.09 | 81.69 | 4.13 | 3.28 | -0.07 | 819.00% | 99.00% | 1135.00% | 4.93% | 1.14 | 16.86% | 0.45% | 8.20% | 5.36% | 21.47 | 18.83 | 5.36 | 7.62 |
| VEEV | Veeva Systems Inc. | $182.01 | 29.92B | +3% | +13% | -70% | -43% | 49.42 | 6.05 | 12.85 | 41.34 | 144.65 | 6.60 | 74.53% | 25.17% | 26.00% | 13.63% | 75.08% | 10.78% | 0.01 | — | 4.51 | 4.44 | -1.43 | 3416.00% | 1620.00% | 2083.00% | 3.03% | 0.78 | 149.51% | 0.00% | 0.00% | 1.12% | 43.70 | 28.25 | 11.00 | 16.19 |
About argenx SE
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
- CEO
- Timothy Van Hauwermeiren
- Employees
- 1.6K
- Beta
- -0.17
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($29,657.82 ÷ $783.50) − 1 = +3,685.3% (DCF, example).